



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Ziextenzo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	C.9 Introduction of, or change(s) to, the	27/03/2026			To update the RMP by removing two identified risks

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000336201	<p>obligations and conditions of a marketing authorisation, including the risk management plan - C.9.z Other variation - Accepted</p> <p>C.9.z (Type IB) – To update the RMP by removing two identified risks (sickle cell crisis in patients with sickle cell disease and glomerulonephritis) from the list of safety concerns, in alignment with the RMP of the reference product Neulasta.</p>				(sickle cell crisis in patients with sickle cell disease and glomerulonephritis) from the list of safety concerns, in alignment with the RMP of the reference product Neulasta.
Variation type IB / EMA/VR/0000257344	<p>This was an application for a group of variations.</p> <p>B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted</p> <p>B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted</p>	08/04/2025			

	<p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted</p>				
PSUR / EMA/PSUR/0000274399					